Tristel plc, the manufacturer of infection prevention products, has announced that the United States Environmental Protection Agency (EPA) has registered its foam-based chlorine dioxide product, Duo.
This registration enables Tristel to market Duo to clean and disinfect hard, non-porous surfaces in the US. The federal registration will be followed by state-by-state approvals which the Tristel expects to complete by the end of 2018. The company anticipates first revenues from the United States during its 2018-19 financial year.
Paul Swinney, Tristel CEO, commented: “We have achieved our first United States regulatory approval, and we will continue to pursue further registrations with the EPA and the Food and Drug Administration (FDA) to build a broadly-based business in the US.”
Tristel recently announced the appointment of Parker Laboratories to manufacture Duo in its FDA approved facility in New Jersey, and to sell Duo into the ultrasound marketplace in which they have national sales coverage. “We will sell our products through different channels into other clinical areas in the USA hospital market,” Swinney pointed out.
Swinney said this first United States approval is a very significant step for Tristel as it enables to access the largest healthcare market in the world.
“It has been our long-held ambition to be recognised as a global brand in the infection prevention industry. An active presence in the United States is necessary to achieve this ambition, and now we can build upon the foundation stone laid in our collaboration with Parker to progress confidently towards our goal,” Swinney concluded.